---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-078135"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:09:24.592646+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# VYNE Q2 net loss $5.8M; cash runway extended to H1 2027; two directors resign

## Summary
- Cash, equivalents and marketable securities $39.6M as of Jun 30, expected to fund ops into first half of 2027.
- Net loss $5.8M ($0.13 per share) vs $9.4M ($0.22) in Q2 2024; revenue $0.1M from Finacea royalty.
- Directors Christine Borowski and Anthony Bruno resigned effective Aug 11 and 13, 2025; no dispute with company.
- Repibresib Phase 2b vitiligo trial missed primary endpoint; company seeking partner for program.
- FDA lifted clinical hold on VYN202 Phase 1b for female subjects; partial hold remains for males pending new toxicology study.

## SEC filing metadata
- accession: 0001104659-25-078135
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465925078135/0001104659-25-078135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465925078135/tm2523400d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-078135
- JSON: https://secwatch.observer/filing/0001104659-25-078135.json
- Plain text: https://secwatch.observer/filing/0001104659-25-078135.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.